Momelotinib

Drug Profile

Momelotinib

Alternative Names: CYT-387; GS-0387; Momelotinib dihydrochloride

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytopia Research
  • Developer Gilead Sciences
  • Class Antineoplastics; Benzamides; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myeloproliferative disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Essential thrombocythaemia; Myelofibrosis; Myeloproliferative disorders; Pancreatic cancer; Polycythaemia vera
  • Phase I Non-small cell lung cancer

Most Recent Events

  • 15 Aug 2017 Gilead Sciences completes a phase II trial for Myelofibrosis, Polycythemia vera and Essential thrombocythemia in USA and Canada (PO) (NCT02515630)
  • 22 Jun 2017 Adverse events data from the phase III SIMPLIFY-I and SIMPLIFY-II trials in Myelofibrosis, essential thrombocythaemia and polycythaemia vera presented at the 22nd Congress of the European Haematology Association (EHA-2017)
  • 02 Jun 2017 Updated adverse events data from the SIMPLIFY-1 phase III trial in Myelofibrosis, essential thrombocythaemia and polycythaemia vera presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top